Literature DB >> 2873851

Medication noncompliance in schizophrenia: codification and update.

J L Young, H V Zonana, L Shepler.   

Abstract

Risk of relapse and recidivism makes the failure to take antipsychotic medication as prescribed a significant issue in forensic psychiatry. This question may arise in such contexts as the setting of bail, plea bargaining, the insanity defense, and sentencing. We have reviewed the literature on medication noncompliance in schizophrenia and present here the results, organized by topics relevant for the work of forensic mental health experts. Reported rates of noncompliance vary widely, reflecting major differences in the populations studied and the methods used as well as the complexities involved in defining noncompliant behavior. A noncompliance rate of 50 percent has been attributed globally to chronic patients, both medical and psychiatric. The tendency of significant factors to interact precludes a simple typology of noncompliance. However, environmental security and supportiveness correlate positively with adherence; whereas anxiety, paranoia, grandiosity, depression, and side effects correlate negatively. Clinicians' assessments of whether medication is being taken have proven to be unreliable. Although monitoring by chemical measurement, particularly a radioreceptor assay for urine samples, can be useful, depot injection ensures that prescribed medication is being taken. Less invasive means of promoting compliance are described; psychodynamic and ethical issues to be considered in the monitoring and promotion of compliance over extended time periods are presented. We also probe the link between medication noncompliance and behavioral relapse. The time between default and relapse is most often measured in weeks. Whether due to medication withdrawal or not, the relapse pattern of each individual tends to repeat, allowing its recognition before recidivism occurs. Restarting medication at this stage, especially with a dosage increase, is usually effective. In sum, the forensic mental health expert can now readily use a large and diverse literature to assist with a variety of significant issues.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873851

Source DB:  PubMed          Journal:  Bull Am Acad Psychiatry Law        ISSN: 0091-634X


  28 in total

1.  A study of treatment outcomes from atypical antipsychotic medications in the Virginia public system of community care.

Authors:  David M Ziegler; Thomas J Peachey
Journal:  Community Ment Health J       Date:  2003-04

2.  Clinical encounters with outpatient coercion at the CMHC: questions of implementation and efficacy.

Authors:  J L Geller
Journal:  Community Ment Health J       Date:  1992-04

3.  Family support predicts psychiatric medication usage among Mexican American individuals with schizophrenia.

Authors:  Jorge I Ramírez García; Christina L Chang; Joshua S Young; Steven R López; Janis H Jenkins
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-05-29       Impact factor: 4.328

4.  The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.

Authors:  Dawn I Velligan; Pamela M Diamond; Jim Mintz; Natalie Maples; Xueying Li; John Zeber; Larry Ereshefsky; Yui-Wing F Lam; Desiree Castillo; Alexander L Miller
Journal:  Schizophr Bull       Date:  2007-10-10       Impact factor: 9.306

5.  WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.

Authors:  Steven M Grauer; Radka Graf; Rachel Navarra; Amy Sung; Sheree F Logue; Gary Stack; Christine Huselton; Zhi Liu; Thomas A Comery; Karen L Marquis; Sharon Rosenzweig-Lipson
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

6.  Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors:  Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

8.  Treatment compliance and hostility levels of head-injured psychiatric outpatients.

Authors:  I M Salloum; E J Jenkins; B Thompson; D Levi; Y Burnett
Journal:  J Natl Med Assoc       Date:  1990-08       Impact factor: 1.798

9.  Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

Authors:  Natalie C Edwards; Marcia F T Rupnow; Chris L Pashos; Marc F Botteman; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.

Authors:  Keith L Shelton; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Drug Alcohol Depend       Date:  2013-01-29       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.